Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0
- Trius Theraputics, San Diego, CA (United States)
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
This was a collaborative effort between Lawrence Livermore National Security, LLC as manager and operator of Lawrence Livermore National Laboratory (LLNL) and Trius Therapeutics, Inc. ("Trius") to develop novel agents for gram-negative biodefense pathogens. LLNL and Trius jointly responded to a U.S. Health and Human Services (National Institutes of Health) request for proposals (solicitation # BAA NIH-NIAID-DMID 08-20) to develop new therapeutic countermeasures with a proposal entitled "Development of Therapeutic Agents for Select Biodefense Pathogens" which resulted in this CRADA, with a goal of developing gram-negative, dual-target antibacterial agents that show no cross-resistance to existing drugs. Trius was awarded Contract HHSN272200800042C to accomplish the goals in the proposal, with LLNL as a major subcontractor.
- Research Organization:
- Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC52-07NA27344
- OSTI ID:
- 1424632
- Report Number(s):
- LLNL-TR-745528; LLNL-TR-638984
- Country of Publication:
- United States
- Language:
- English
Similar Records
Design of Genomic Signatures of Pathogen Identification & Characterization
The Autonomous Pathogen Detection System (APDS)